發(fā)布者：抗性基因網(wǎng) 時間：2023-06-12 瀏覽量：476
摘要
? ? ? 普氏糞桿菌是一種有益的人類腸道微生物，也是下一代益生菌的候選菌。隨著益生菌目前被用于臨床治療，需要考慮其安全性和副作用。因此，有必要全面了解不同菌株的遺傳多樣性、功能特征和潛在風(fēng)險。在本研究中，我們收集了84F的遺傳信息。從多個角度進行普氏菌的全基因組分析。基于單拷貝基因、16S rRNA序列和泛基因組組成，對不同菌株進行了系統(tǒng)發(fā)育分析，顯示了它們之間的遺傳多樣性。在泛基因組的蛋白質(zhì)中，我們發(fā)現(xiàn)副簇比核心簇和特定簇對普氏F.prausnitzii菌株的主要遺傳功能的貢獻更大。prausnitzii的功能注釋表明，只有極少數(shù)蛋白質(zhì)與人類疾病有關(guān)，并且沒有編碼有害產(chǎn)物的次級代謝基因簇。同時，在馬齒莧中檢測到完全的脂肪酸代謝。此外，我們檢測了包括抗生素耐藥性基因、毒力因子和致病基因在內(nèi)的有害元素，并提出了益生菌潛在風(fēng)險指數(shù)（PPRI）和益生菌潛在風(fēng)險評分（PPRS），將這84株菌株分為低、中、高風(fēng)險組。最后，15株菌株被確定為低風(fēng)險菌株，并優(yōu)先用于臨床應(yīng)用。毫無疑問，我們的研究結(jié)果提供了對普氏F.prausnitzii的全面理解和見解，PPRI和PPRS可用于評估益生菌的潛在風(fēng)險，并指導(dǎo)益生菌在臨床應(yīng)用中的應(yīng)用。Faecalibacterium prausnitzii is a beneficial human gut microbe and a candidate for next-generation probiotics. With probiotics now being used in clinical treatments, concerns about their safety and side effects need to be considered. Therefore, it is essential to obtain a comprehensive understanding of the genetic diversity, functional characteristics, and potential risks of different F. prausnitzii strains. In this study, we collected the genetic information of 84 F . prausnitzii strains to conduct a pan-genome analysis with multiple perspectives. Based on single-copy genes and the sequences of 16S rRNA and the compositions of the pan-genome, different phylogenetic analyses of F. prausnitzii strains were performed, which showed the genetic diversity among them. Among the proteins of the pan-genome, we found that the accessory clusters made a greater contribution to the primary genetic functions of F. prausnitzii strains than the core and specific clusters. The functional annotations of F. prausnitzii showed that only a very small number of proteins were related to human diseases and there were no secondary metabolic gene clusters encoding harmful products. At the same time, complete fatty acid metabolism was detected in F. prausnitzii. In addition, we detected harmful elements, including antibiotic resistance genes, virulence factors, and pathogenic genes, and proposed the probiotic potential risk index (PPRI) and probiotic potential risk score (PPRS) to classify these 84 strains into low-, medium-, and high-risk groups. Finally, 15 strains were identified as low-risk strains and prioritized for clinical application. Undoubtedly, our results provide a comprehensive understanding and insight into F. prausnitzii, and PPRI and PPRS can be applied to evaluate the potential risks of probiotics in general and to guide the application of probiotics in clinical application.
https://www.frontiersin.org/articles/10.3389/fcimb.2022.919701/full?utm_source=dlvr.it&utm_medium=twitter